Mary Bach1, Jeonghun Moon2, Richard Moore1, Tiffany Pan3, J Lee Nelson4, Christian Lood1. 1. University of Washington, Seattle. 2. The Polyclinic, Seattle, Washington. 3. Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract
OBJECTIVE: Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs) are linked to inflammation and autoimmunity, including rheumatoid arthritis (RA). However, whether NETs are present in the circulation of RA patients and contribute to inflammation and disease progression has not been carefully addressed. We undertook this study to assess markers of neutrophil activation and NET formation in plasma samples, investigating whether they add clinical value in improving the determination of prognosis and monitoring in RA patients. METHODS: Markers of neutrophil activation (calprotectin) and cell death (NETs) were analyzed, using enzyme-linked immunosorbent assay, in serum and plasma obtained from patients in 3 cross-sectional RA cohorts and sex-matched healthy controls. A longitudinal inception cohort (n = 247), seen for a median follow-up of 8 years, was used for predictive analyses. RESULTS: Markers of neutrophil activation and cell death were increased in RA patients compared to healthy individuals (P < 0.0001). Calprotectin levels correlated with the Clinical Disease Activity Index (r = 0.53, P < 0.0001) and could be used to distinguish between patients with disease in remission and those with active disease, an observation not seen when examining C-reactive protein levels. A biomarker panel consisting of anti-citrullinated protein antibody and calprotectin could predict erosive disease (odds ratio [OR] 7.5, P < 0.0001) and joint space narrowing (OR 4.9, P = 0.001). NET levels were associated with markers of inflammation (P = 0.0002). Furthermore, NETs and a "neutrophil activation signature" biomarker panel had good predictive value in identifying patients who were developing extraarticular nodules (OR 5.6, P = 0.006). CONCLUSION: Neutrophils undergo marked activation and cell death in RA. Neutrophil biomarkers can provide added clinical value in the monitoring and prognosis of RA patients and may allow for early preventive treatment intervention.
OBJECTIVE: Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs) are linked to inflammation and autoimmunity, including rheumatoid arthritis (RA). However, whether NETs are present in the circulation of RApatients and contribute to inflammation and disease progression has not been carefully addressed. We undertook this study to assess markers of neutrophil activation and NET formation in plasma samples, investigating whether they add clinical value in improving the determination of prognosis and monitoring in RApatients. METHODS: Markers of neutrophil activation (calprotectin) and cell death (NETs) were analyzed, using enzyme-linked immunosorbent assay, in serum and plasma obtained from patients in 3 cross-sectional RA cohorts and sex-matched healthy controls. A longitudinal inception cohort (n = 247), seen for a median follow-up of 8 years, was used for predictive analyses. RESULTS: Markers of neutrophil activation and cell death were increased in RApatients compared to healthy individuals (P < 0.0001). Calprotectin levels correlated with the Clinical Disease Activity Index (r = 0.53, P < 0.0001) and could be used to distinguish between patients with disease in remission and those with active disease, an observation not seen when examining C-reactive protein levels. A biomarker panel consisting of anti-citrullinated protein antibody and calprotectin could predict erosive disease (odds ratio [OR] 7.5, P < 0.0001) and joint space narrowing (OR 4.9, P = 0.001). NET levels were associated with markers of inflammation (P = 0.0002). Furthermore, NETs and a "neutrophil activation signature" biomarker panel had good predictive value in identifying patients who were developing extraarticular nodules (OR 5.6, P = 0.006). CONCLUSION: Neutrophils undergo marked activation and cell death in RA. Neutrophil biomarkers can provide added clinical value in the monitoring and prognosis of RApatients and may allow for early preventive treatment intervention.
Authors: Abdul Hakkim; Barbara G Fürnrohr; Kerstin Amann; Britta Laube; Ulrike Abu Abed; Volker Brinkmann; Martin Herrmann; Reinhard E Voll; Arturo Zychlinsky Journal: Proc Natl Acad Sci U S A Date: 2010-05-03 Impact factor: 11.205
Authors: Gina S Garcia-Romo; Simone Caielli; Barbara Vega; John Connolly; Florence Allantaz; Zhaohui Xu; Marilynn Punaro; Jeanine Baisch; Cristiana Guiducci; Robert L Coffman; Franck J Barrat; Jacques Banchereau; Virginia Pascual Journal: Sci Transl Med Date: 2011-03-09 Impact factor: 17.956
Authors: Jonatan Leffler; Birgitta Gullstrand; Andreas Jönsen; Jan-Åke Nilsson; Myriam Martin; Anna M Blom; Anders A Bengtsson Journal: Arthritis Res Ther Date: 2013-08-14 Impact factor: 5.156
Authors: Despina Michailidou; Bhargavi Duvvuri; Runa Kuley; David Cuthbertson; Peter C Grayson; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Kenneth J Warrington; Tomas Mustelin; Paul A Monach; Peter A Merkel; Christian Lood Journal: Arthritis Res Ther Date: 2022-06-29 Impact factor: 5.606
Authors: Nancy Wareing; Vishnu Mohan; Rana Taherian; Elizabeth R Volkmann; Marka A Lyons; Holly Wilhalme; Michael D Roth; Rosa M Estrada-Y-Martin; Brian Skaug; Maureen D Mayes; Donald P Tashkin; Shervin Assassi Journal: Arthritis Care Res (Hoboken) Date: 2022-03-14 Impact factor: 5.178
Authors: Bhargavi Duvvuri; Al Anoud Baddour; Kevin D Deane; Marie L Feser; J Lee Nelson; M Kristen Demoruelle; Christian Lood Journal: J Autoimmun Date: 2021-03-10 Impact factor: 7.094
Authors: D Vedder; M Gerritsen; B Duvvuri; R F van Vollenhoven; M T Nurmohamed; C Lood Journal: Arthritis Res Ther Date: 2020-06-18 Impact factor: 5.156
Authors: Xiaoxing Wang; Amanda Hefton; Kathryn Ni; Kennedy C Ukadike; Michael A Bowen; Mary Eckert; Anne Stevens; Christian Lood; Tomas Mustelin Journal: J Rheumatol Date: 2021-08-01 Impact factor: 4.666
Authors: Christian Lood; Tomas Mustelin; Kennedy C Ukadike; Kathryn Ni; Xiaoxing Wang; Martin S Taylor; John LaCava; Lauren M Pachman; Mary Eckert; Anne Stevens Journal: Arthritis Res Ther Date: 2021-05-29 Impact factor: 5.156
Authors: Matthias Jarlborg; Delphine S Courvoisier; Céline Lamacchia; Laura Martinez Prat; Michael Mahler; Chelsea Bentow; Axel Finckh; Cem Gabay; Michael J Nissen Journal: Arthritis Res Ther Date: 2020-05-06 Impact factor: 5.156